News

Mapping tumor microenvironments to predict lung cancer immunotherapy response
Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...
Maintenance lurbinectedin + atezolizumab enhances survival in lung cancer
Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell ...
Pharmabiz10h
EMA committee recommends approval of AstraZeneca’s Imfinzi to treat adult patients with resectable muscle-invasive bladder cancer
EMA committee recommends approval of AstraZeneca’s Imfinzi to treat adult patients with resectable muscle-invasive bladder cancer: Cambridge, UK Tuesday, May 27, 2025, 15:00 Hrs ...
ORYZON to Provide Corporate Progress Updates at Several Events in May-June
Foro MedCap 2025BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ...